Ayer, Genentech, Merck, Myriad, and Pfizer; getting lecture payments from Boehringer Ingelheim and Medscape; and receiving payments for developing educational presentations from Pfizer. Dr Varella-Garcia reports receiving honoraria, study funding, and payments for building educational presentations from Abbott Molecular. Mr Aronson reports receiving grant funding in the Lung Cancer Mutation Consortium to her institution; receiving lecture fees from Leerink Swann; his institution, Partners HealthCare, licensed the GeneInsight technologies in November 2012 to a organization in which it acquired 100 equity ownership. This transaction was reviewed by the Partners Committee on Conflicts of Interest in light of Partners acquisition of this monetary interest, along with the Committee, consistent with Partners policy, expected that notice of Partners economic interest in the technologies be offered to journals and in publications and presentations on the technology. Partners established a partnership with Illumina related for the GeneInsight application that was in effect for the duration of this function. Dr Sequist reports consulting for AstraZeneca, Boehringer Ingelheim, Clovis Oncology, GlaxoSmithKline, and Merrimack Pharmaceuticals. Dr Garon reports consulting for Boehringer Ingelheim and receiving grant funding from AstraZeneca, Eli Lilly, Genentech, Novartis, Pfizer, and Puma Biotechnology.(2-Cyclopropylpyridin-4-yl)boronic acid web Dr Pao reports consulting for AstraZeneca, Bristol-Myers Squibb, Champions, Clarient, Clovis Oncology, Evolution, Exelixis, MolecularMD, and Symphony; getting analysis funding from AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Enzon, Symphogen, and Xcovery; getting payment for the development of educational presentations for the International Association for the Study of Lung Cancer and WebMD; serving on panels and as a grant reviewer for the American Association for Cancer Analysis, Uniting Against Lung Cancer, the American Society of Clinical Oncology, and also the National Complete Cancer Network; and receiving remuneration and patent royalties from rights to EGFR T790M testing was licensed on behalf of himself and other people by Memorial Sloan Kettering Cancer Center to MolecularMD.1223105-51-8 In stock Dr Rudin reports consulting for Celgene and Oncothyreon.PMID:24633055 Dr Schiller reports consulting for AdventRX, Aggenix, Ariad, Arquile, AVEO, Biodesix, Boehringer Ingelheim, Clovis, Dekkun, EMD Serono, Genentech, GlaxoSmithKline, Merck, Novartis, Peregrine, Pfizer, Synta, and Threshold Pharmaceuticals; and receiving grant funding from Astex, Endocyte, Genentech, Geron, Merrimack, Novartis, and Synta. Dr Shirai reports getting lecture charges from Bristol-Myers Squibb. Dr Ladanyi reports consulting for NanoString, Novartis, Puma Biotechnology and getting lecture payments from Remedica Healthcare Education. Dr Minna reports consulting for Amgen; receiving royalties in the National Institutes of Well being (NIH) and Genentech for the licensing of lung cancer cell lines; serving around the grant evaluation board of the V Foundation; getting travel and accommodations from the International Association for the Study of Lung Cancer; and holding NIH grants related to lung cancer. Dr Bunn reports consulting for Amgen, Astellas Pharma, AstraZeneca,Bayer,BoehringerIngelheim, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Merck, Merck Serono, Merrimack, Myriad Genetics, Pfizer, Roche/Genentech, sanofi-aventis, and Synta. No other disclosures are reported. Previous Presentation: Prese.